<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04234321</url>
  </required_header>
  <id_info>
    <org_study_id>IR201900069</org_study_id>
    <nct_id>NCT04234321</nct_id>
  </id_info>
  <brief_title>Clinical Study of Kangfuxin and Basic Fibroblast Growth Factor in Promoting the Healing of Donor Site</brief_title>
  <official_title>A Multicenter, Prospective Clinical Study of Kangfuxin and Basic Fibroblast Growth Factor in Promoting the Healing of Donor Site</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>The Second Affiliated Hospital of Kunming Medical University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Jiangyin Hospital Affiliated to Southeast University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Nantong University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>The 59th Central Hospital of the Chinese people's Liberation Army</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Taizhou Central Hospital (Taizhou University Hospital)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Zhejiang Quhua Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Lishui Country People's Hospital</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The main objective of this study is to observe whether basic fibroblast growth factor and
      Kangfuxin Liquid can promote the wound healing in the donor area and further evaluate the
      healing quality.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">August 1, 2020</start_date>
  <completion_date type="Anticipated">December 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Wound healing rate</measure>
    <time_frame>up to 2 or 3 weeks</time_frame>
    <description>Means (wound area before treatment - wound area after treatment) / wound area before treatment × 100%.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Actual healing time</measure>
    <time_frame>up to 2 or 3 weeks</time_frame>
    <description>Means time of complete wound healing</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Degree of scar formation</measure>
    <time_frame>up to 3 or 12 weeks</time_frame>
    <description>The degree of scar formation .</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Fibroblast Growth Factors</condition>
  <condition>Wound Healing</condition>
  <arm_group>
    <arm_group_label>basic fibroblast growth factor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Kangfuxin Liquid</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>0.9% Normal saline</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>0.9% Normal saline,20ml / 100cm2 / time,three times a day.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>basic fibroblast growth factor</intervention_name>
    <description>Basic fibroblast growth factor,100ml/ bottle, (35000IU / 8ml) / 100cm2 / time,three times a day.</description>
    <arm_group_label>basic fibroblast growth factor</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Kangfuxin Liquid</intervention_name>
    <description>Kangfuxin Liquid,20ml / 100cm2 / time,three times a day.</description>
    <arm_group_label>Kangfuxin Liquid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.9% Normal saline</intervention_name>
    <description>0.9% Normal saline,20ml / 100cm2 / time,three times a day.</description>
    <arm_group_label>0.9% Normal saline</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male / female patients aged 20-50;

          -  Burn area ≤ 30% TBSA;

          -  Patients who need auto skin grafting due to burns or skin defects due to trauma;

          -  The donor area is 100cm2, and the thickness of skin is 0.25mm (Split thickness skin
             donor site group)/0.40mm (Medium thickness skin donor site group). The donor site is
             the body part with similar skin color and sufficient skin area (except scalp);

          -  Not involved in clinical trials of other drugs;

          -  Subjects who have agreed to participate in the clinical study and signed the informed
             consent.

        Exclusion Criteria:

          -  Subjects who were previously allergic to similar products or related components of
             test products;

          -  Subjects with other systemic or local skin diseases that may affect wound evaluation;

          -  Subjects with significant organ dysfunction / failure or other serious diseases,
             including clinical related cardiovascular disease or myocardial infarction within 12
             months before enrollment; malignant tumor; serious neurological or psychiatric
             history; serious infection; active disseminated intravascular coagulation;

          -  Subjects with moderate malnutrition (BMI &lt; 17kg / m2) and severe anemia (HB &lt; 60g /
             L);

          -  Subjects proposed to use immunosuppressant, steroid hormone, epidermal growth factor
             and other drugs that may affect the wound healing of the donor skin within 3 months
             before admission or during the study period;

          -  Participated in clinical trials of any other drugs or medical devices within 3 months;

          -  History of major diseases that may affect general physical condition and other
             patients who are not considered by the researchers to be eligible for this study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>huawei shao, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>huawei shao, MD</last_name>
    <phone>13989880761</phone>
    <phone_ext>+86</phone_ext>
    <email>2504131@zju.edu.cn</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>chunmao han, MD</last_name>
    <phone>0571 87783759</phone>
    <phone_ext>+86</phone_ext>
    <email>hanchunmao1@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>2nd Affiliated Hospital, School of Medicine, Zhejiang University, China</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>huawei shao, MD</last_name>
      <phone>13989880761</phone>
      <phone_ext>+86</phone_ext>
      <email>2504131@zju.edu.cn</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>January 4, 2020</study_first_submitted>
  <study_first_submitted_qc>January 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">January 21, 2020</study_first_posted>
  <last_update_submitted>May 8, 2020</last_update_submitted>
  <last_update_submitted_qc>May 8, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">May 12, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>basic fibroblast growth factor,Kangfuxin,Wound Healing</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Mitogens</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

